Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 14, 2018 08:30 ET | Source: Endonovo Therapeutics, Inc.

Endonovo Therapeutics Announces Enrollment of First Patient in Clinical Study at the University of New Mexico for Treating Traumatic Brain Injury Using Its Electroceutical™ Therapy

LOS ANGELES, CA, June 14, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of Electroceutical™ Therapies, today...
May 11, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)

PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that its European subsidiary, Hemispherx Biopharma Europe N.V./S.A.,...
March 24, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)

PHILADELPHIA, March 24, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European subsidiary, "Hemispherx Biopharma Europe...
December 09, 2014 09:51 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen(R) Enlarged by Howard University Research

PHILADELPHIA, Dec. 9, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that it has received a new research report (dated December 5,...
October 30, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Reports New Evidence -- Based Potential of Ampligen(R) Against Ebola Virus Disease (EVD)

PHILADELPHIA, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today a new peer reviewed publication entitled, "The Quest for...